Carvedilol, a nonselective β-blocker, suppresses the production of tumor necrosis factor and tissue factor by inhibiting early growth response factor-1 expression in human monocytes in vitro

Translational Research

Volumn 149, Issue 4, 2007, Pages 223-230

  Mizuochi, Yuichiro ^a   Okajima, Kenji ^a   Harada, Naoaki ^a   Molor Erdene, Perenlei ^b   Uchiba, Mitsuhiro ^b   Komura, Hidefumi ^a   Tsuda, Takako ^a   Katsuya, Hirotada ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AROTINOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; EARLY GROWTH RESPONSE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; PRAZOSIN; THROMBOPLASTIN; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR;

ARTICLE; CELL ISOLATION; CELL STIMULATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE INACTIVATION; GENE REPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOCYTE; PRIORITY JOURNAL;

EID: 33947302872     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2006.11.008     Document Type: Article

References (50)

1. Cohn J.N., Levine T.B., Francis G.S., and Goldsmith S. Neurohumoral control mechanisms in congestive heart failure. Am Heart J 102 (1981) 509-514
2. Cohn J.N., Levine T.B., Olivari M.T., Garberg V., Lura D., Francis G.S., et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311 (1984) 819-823
3. Mann D.L., and Young J.B. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. Chest 105 (1994) 897-904
4. Seta Y., Shan K., Bozkurt B., Oral H., and Mann D.L. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 2 (1996) 243-249
5. Feldman A.M., Combes A., Wagner D., Kadakomi T., Kubota T., Li Y.Y., et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 35 (2000) 537-544
6. Testa M., Yeh M., Lee P., Fanelli R., Loperfido F., Berman J.W., et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 28 (1996) 964-971
7. Torre-Amione G., Kapadia S., Benedict C., Oral H., Young J.B., and Mann D.L. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27 (1996) 1201-1206
8. Deswal A., Petersen N.J., Feldman A.M., Young J.B., White B.G., and Mann D.L. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103 (2001) 2055-2059
9. Finkel M.S., Oddis C.V., Jacob T.D., Watkins S.C., Hattler B.G., and Simmons R.L. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 257 (1992) 387-389
10. Yokoyama T., Vaca L., Rossen R.D., Durante W., Hazarika P., and Mann D.L. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 92 (1993) 2303-2312
11. Mann D.L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 91 (2002) 988-998
12. Uretsky B.F., Thygesen K., Armstrong P.W., Cleland J.G., Horowitz J.D., Massie B.M., et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation 102 (2000) 611-616
13. Lip G.Y., and Gibbs C.R. Does heart failure confer a hypercoagulable state?. Virchow's triad revisited. J Am Coll Cardiol 33 (1999) 1424-1426
14. Loh E., Sutton M.S., Wun C.C., Rouleau J.L., Flaker G.C., Gottlieb S.S., et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 336 (1997) 251-257
15. Narang R., Cleland J.G., Erhardt L., Ball S.G., Coats A.J., Cowley A.J., et al. Mode of death in chronic heart failure. A request and proposition for more accurate classification. Eur Heart J 17 (1996) 1390-1403
16. Osterud B. Tissue factor expression by monocytes: regulation and pathophysiological roles. Blood Coagul Fibrinolysis 9 suppl 1 (1998) S9-S14
17. Chin B.S., Blann A.D., Gibbs C.R., Chung N.A., Conway D.G., and Lip G.Y. Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure. Eur J Clin Invest 33 (2003) 941-948
18. Niebauer J., Volk H.D., Kemp M., Dominguez M., Schumann R.R., Rauchhaus M., et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 353 (1999) 1838-1842
19. Guha M., and Mackman N. LPS induction of gene expression in human monocytes. Cell Signal 13 (2001) 85-94
20. Mackman N. Regulation of the tissue factor gene. Thromb Haemost 78 (1997) 747-754
21. Yao J., Mackman N., Edgington T.S., and Fan S.T. Lipopolysaccharide induction of the tumor necrosis factor-alpha promoter in human monocytic cells. Regulation by Egr-1, c-Jun, and NF-κB transcription factors. J Biol Chem 272 (1997) 17795-17801
22. Nichols A.J., Sulpizio A.C., Ashton D.J., Hieble J.P., and Ruffolo Jr. R.R. In vitro pharmacologic profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilol. Pharmacology 39 (1989) 327-336
23. Packer M., Coats A.J., Fowler M.B., Katus H.A., Krum H., Mohacsi P., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001) 1651-1658
24. Cinquegrana G., D'Aniello L., Landi M., Spinelli L., Grande G., De Prisco F., et al. Effects of different degrees of sympathetic antagonism on cytokine network in patients with ischemic dilated cardiomyopathy. J Card Fail 11 (2005) 213-219
25. Poole-Wilson P.A., Swedberg K., Cleland J.G., Di Lenarda A., Hanrath P., Komajda M., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362 (2003) 7-13
26. Cleland J.G., and Swedberg K. Carvedilol for heart failure, with care. Lancet 347 (1996) 1199-1201
27. Uchiba M., Okajima K., Murakami K., Okabe H., and Takatsuki K. Effect of nafamostat mesilate on pulmonary vascular injury induced by lipopolysaccharide in rats. Am J Respir Crit Care Med 155 (1997) 711-718
28. Molor-Erdene P., Okajima K., Isobe H., Uchiba M., Harada N., Shimozawa N., et al. Inhibition of lipopolysaccharide-induced tissue factor expression in monocytes by urinary trypsin inhibitor in vitro and in vivo. Thromb Haemost 94 (2005) 136-145
29. Molor-Erdene P., Okajima K., Isobe H., Uchiba M., Harada N., and Okabe H. Urinary trypsin inhibitor reduces LPS-induced hypotension by suppressing tumor necrosis factor-alpha production through inhibition of Egr-1 expression. Am J Physiol Heart Circ Physiol 288 (2005) H1265-H1271
30. Yang S.P., Ho L.J., Cheng S.M., Hsu Y.L., Tsao T.P., Chang D.M., et al. Carvedilol differentially regulates cytokine production from activated human peripheral blood mononuclear cells. Cardiovasc Drugs Ther 18 (2004) 183-188
31. Baldwin Jr. A.S. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 14 (1996) 649-683
32. Whitmarsh A.J., and Davis R.J. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med 74 (1996) 589-607
33. Guha M., O'Connell M.A., Pawlinski R., Hollis A., McGovern P., Yan S.F., et al. Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression. Blood 98 (2001) 1429-1439
34. Shi L., Kishore R., McMullen M.R., and Nagy L.E. Lipopolysaccharide stimulation of ERK1/2 increases TNF-alpha production via Egr-1. Am J Physiol Cell Physiol 282 (2002) C1205-C1211
35. Sung C.P., Arleth A.J., Eichman C., Truneh A., and Ohlstein E.H. Carvedilol, a multiple-action neurohumoral antagonist, inhibits mitogen-activated protein kinase and cell cycle progression in vascular smooth muscle cells. J Pharmacol Exp Ther 283 (1997) 910-917
36. Chung E.S., Packer M., Lo K.H., Fasanmade A.A., and Willerson J.T. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107 (2003) 3133-3140
37. Mann D.L., McMurray J.J., Packer M., Swedberg K., Borer J.S., Colucci W.S., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109 (2004) 1594-1602
38. Scallon B.J., Moore M.A., Trinh H., Knight D.M., and Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7 (1995) 251-259
39. Evans T.J., Moyes D., Carpenter A., Martin R., Loetscher H., Lesslauer W., et al. Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J Exp Med 180 (1994) 2173-2179
40. Kurrelmeyer K.M., Michael L.H., Baumgarten G., Taffet G.E., Peschon J.J., Sivasubramanian N., et al. Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci U S A 97 (2000) 5456-5461
41. Sack M.N., Smith R.M., and Opie L.H. Tumor necrosis factor in myocardial hypertrophy and ischaemia-an anti-apoptotic perspective. Cardiovasc Res 45 (2000) 688-695
42. van der Harst P., Voors A.A., van Gilst W.H., Bohm M., and van Veldhuisen D.J. Statins in the treatment of chronic heart failure: a systematic review. PLoS Med 3 (2006) e333
43. Batchelder K., and Mayosi B.M. Pentoxifylline for heart failure: a systematic review. S Afr Med J 95 (2005) 171-175
44. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 24 (2004) 1015-1022
45. Wilcox J.N., Smith K.M., Schwartz S.M., and Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 86 (1989) 2839-2843
46. McPhillips J.J., Schwemer G.T., Scott D.I., Zinny M., and Patterson D. Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose response study. Drugs 36 suppl 6 (1988) 82-91
47. Yue T.L., Ma X.L., Gu J.L., Ruffolo Jr. R.R., and Feuerstein G.Z. Carvedilol inhibits activation of stress-activated protein kinase and reduces reperfusion injury in perfused rabbit heart. Eur J Pharmacol 345 (1998) 61-65
48. Harada N., Okajima K., and Kushimoto S. Gabexate mesilate, a synthetic protease inhibitor, reduces ischemia/reperfusion injury of rat liver by inhibiting leukocyte activation. Crit Care Med 27 (1999) 1958-1964
49. Harada N., Okajima K., Murakami K., Usune S., Sato C., Ohshima K., et al. Adenosine and selective A(2A) receptor agonists reduce ischemia/reperfusion injury of rat liver mainly by inhibiting leukocyte activation. J Pharmacol Exp Ther 294 (2000) 1034-1042
50. Li B., Liao Y.H., Cheng X., Ge H., Guo H., and Wang M. Effects of carvedilol on cardiac cytokines expression and remodeling in rat with acute myocardial infarction. Int J Cardiol 111 (2006) 247-255